Curex Prescription / Intake Process: A Clinical Review

What Is Curex and Is It a Legitimate Platform?

Curex operates as a direct-to-consumer telehealth company focused on GLP-1 receptor agonist prescriptions for weight management. The platform is not a pharmacy itself. Licensed nurse practitioners or physicians employed or contracted through the service review intake questionnaires and, when clinically appropriate, write prescriptions fulfilled by third-party compounding pharmacies.

Telehealth prescribing of controlled and non-controlled medications is governed by the Ryan Haight Online Pharmacy Consumer Protection Act and, since 2023, by updated DEA telemedicine prescribing rules. GLP-1 agonists like semaglutide are not controlled substances, so a video visit is not legally required, though it remains best clinical practice. Curex's asynchronous model is legal but places more responsibility on the intake form to capture contraindications accurately.

How the Legitimacy Question Should Be Framed

"Legitimate" covers two distinct questions: Is the company legally operating? And does it meet a clinical standard of care?

On the legal question, the answer is likely yes, provided Curex's prescribers hold valid state licenses and the dispensing pharmacies hold 503A or 503B accreditation. The FDA's guidance on compounded semaglutide during the drug shortage period [1] created a narrow legal window for these prescriptions. That window began to close in early 2025 when the FDA removed injectable semaglutide from its shortage list [2], which means platforms relying on compounded versions face tightening legal exposure.

On the clinical-standard question, the answer is more nuanced. The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines recommend a comprehensive evaluation including cardiovascular history, thyroid history (given GLP-1 contraindications), and baseline metabolic labs before initiating therapy [3]. Whether Curex's asynchronous questionnaire consistently captures all of that is not verifiable from public information.

Red Flags Any Patient Should Check

Before signing up with any GLP-1 telehealth platform, patients should confirm the pharmacy is accredited by PCAB (Pharmacy Compounding Accreditation Board) or carries a valid 503B FDA-registered outsourcing facility designation. They should ask for the prescriber's name and license number. And they should verify the compounded product contains semaglutide base, not a salt form like semaglutide sodium, which the FDA flagged in a 2024 guidance as not a permitted compounded ingredient [4].

The Curex Intake Process, Step by Step

The intake process at Curex follows a structure common to most GLP-1 telehealth startups, with some platform-specific details.

Step 1: Online Health Questionnaire

Patients complete a digital intake form covering weight history, current BMI, comorbidities (type 2 diabetes, hypertension, dyslipidemia), prior GLP-1 use, and contraindications. Contraindications to semaglutide include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2), and known hypersensitivity to the drug [5]. The form is the primary clinical filter. Its accuracy depends entirely on patient self-report.

Step 2: Prescriber Review

A contracted clinician reviews the submitted information asynchronously. This is not a real-time conversation in the standard Curex flow, though some patients report being offered a video call option for complex cases. The review window is typically 24 to 48 hours. If the prescriber finds no disqualifying factors, a prescription is generated.

Step 3: Prescription Fulfillment

The prescription routes to a partnered compounding pharmacy. Most compounded semaglutide products are formulated as subcutaneous injections supplied in multi-dose vials. Patients self-administer weekly injections. The starting dose is typically 0.25 mg per week for four weeks, titrating upward in a schedule that mirrors the approved Ozempic or Wegovy titration schedules, though the compounded product is not bioequivalent-tested to those brand products.

Step 4: Ongoing Management

Follow-up protocols vary. Some telehealth platforms include monthly check-ins; others charge separately for follow-up visits. Patients should ask specifically what monitoring Curex includes for side effects like nausea, vomiting, gastroparesis risk, and the rare but serious risk of acute pancreatitis. The STEP-1 trial protocol included structured safety assessments at every visit [6]. A telehealth asynchronous model should replicate that structure, even if the delivery method differs.

What Does Curex Actually Prescribe?

The primary product is compounded semaglutide for weight loss, dosed weekly by subcutaneous injection. Some platforms in this space also offer:

• Tirzepatide (compounded), a dual GIP/GLP-1 agonist approved as Mounjaro (diabetes) and Zepbound (obesity)
• Metformin as an adjunct
• Vitamin B12 added to the semaglutide vial (common in compounded formulations, though clinical benefit of this addition is unestablished)

Semaglutide: The Clinical Evidence Base

The STEP-1 trial (N=1,961) tested subcutaneous semaglutide 2.4 mg once weekly versus placebo in adults with a BMI ≥30 or ≥27 with at least one weight-related comorbidity, without type 2 diabetes. At 68 weeks, the semaglutide group achieved 14.9% mean body weight reduction versus 2.4% with placebo (P<0.001) [6]. That is the benchmark for what the drug class can do under trial conditions.

Compounded semaglutide is not the same product tested in STEP-1. Wilding et al. (2021) tested subcutaneous semaglutide manufactured by Novo Nordisk under controlled pharmaceutical conditions. A compounded version from a 503A pharmacy does not undergo the same sterility, potency, or bioequivalence testing. The FDA has explicitly stated that compounded drugs are not FDA-approved and have not been shown to be safe or effective [7].

Tirzepatide: An Emerging Option

The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% placebo (P<0.001) [8]. Tirzepatide's dual mechanism targeting both GIP and GLP-1 receptors appears to produce meaningfully greater weight loss than semaglutide monotherapy, though head-to-head data are still limited. If Curex offers compounded tirzepatide, the same regulatory caveats apply.

How Much Does Curex Cost?

Published pricing for Curex fluctuates and is not always transparent before the intake process begins. Based on publicly reported patient experiences and competitor benchmarking, the approximate cost structure looks like this:

• Initial consultation fee: $0 to $75
• Monthly medication cost (compounded semaglutide): $199 to $399 per month depending on dose tier
• Follow-up visit fees: sometimes bundled, sometimes billed separately

Compare that to brand-name Wegovy (semaglutide 2.4 mg), which lists at approximately $1,349 per month before insurance or manufacturer savings programs. The Novo Nordisk savings card can bring that to $0 for commercially insured patients who qualify [9]. For uninsured patients, compounded options offer a genuine cost reduction, though with the trade-offs described above.

The GoodRx price for brand Ozempic (semaglutide 0.5 to 2 mg, diabetes indication) runs $850 to $1,000 per month without insurance, reinforcing why cash-pay compounded options attract patients [10].

The table below provides a rough decision framework for evaluating whether compounded GLP-1 telehealth is appropriate for a given patient's situation.

| Patient Profile | Recommended Path | |---|---| | Commercially insured, BMI ≥30 | Pursue brand Wegovy with insurance prior auth first | | Medicare/Medicaid enrollee | Note: Medicare Part D covers Wegovy for CVD indication (post-SELECT trial approval) [11] | | Uninsured or underinsured, no access to brand | Compounded option may be pragmatic; verify pharmacy accreditation | | History of MTC or MEN2 | No GLP-1 agonist regardless of source | | Type 2 diabetes, needs GLP-1 | Ozempic or Mounjaro likely covered; telehealth may still apply | | Prior pancreatitis | Proceed only with specialist clearance |

Curex vs. Alternatives: How Does It Compare?

The GLP-1 telehealth market now includes Hims and Hers Health, Ro, Found, Noom Med, Sequence (now part of WeightWatchers), and dozens of smaller operators. Differentiating them requires looking at three variables: clinical rigor of intake, pharmacy transparency, and continuity of care.

Clinical Intake Rigor

Ro and Found both advertise synchronous video visits as part of their standard intake. Hims and Hers has faced regulatory scrutiny over its compounding practices [12]. Sequence requires patients to connect with an in-network insurance-covered prescriber where possible. Curex's asynchronous-first model is faster and cheaper but skips the back-and-forth that catches edge cases a form misses.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should evaluate patients for contraindications and potential drug interactions before initiating GLP-1 receptor agonist therapy, including a focused personal and family history for thyroid cancer" [13]. An asynchronous questionnaire can collect that history, but cannot probe ambiguous answers the way a clinician conversation can.

Pharmacy Transparency

Patients comparing platforms should ask each one: What is the name of the dispensing pharmacy? Is it 503A or 503B registered? Can I verify its registration on the FDA's website? The FDA maintains a public list of registered 503B outsourcing facilities [14]. Any platform unwilling to name its pharmacy is a concern.

Continuity of Care

Weight management is a chronic condition. The STEP-1 trial showed that patients who discontinued semaglutide regained two-thirds of their lost weight within one year [15]. That means the prescribing relationship needs to last years, not months. Patients should ask whether Curex's model supports long-term prescribing or whether the business model is oriented toward a short initial subscription.

GLP-1 Weight Loss: What the Evidence Actually Says About Outcomes

The drug class works. The evidence for that is strong and consistent across multiple Phase 3 trials. But real-world outcomes at telehealth platforms differ from trial outcomes for several reasons worth understanding.

Adherence and Titration

Trial participants receive structured titration support and frequent follow-up. STEP-1 protocol included visits at weeks 2, 4, 8, 12, 20, 28, 40, 52, and 68 [6]. In a telehealth setting with asynchronous follow-up, patients who experience early side effects like nausea or injection-site reactions may self-discontinue before reaching the therapeutic dose of 2.4 mg. The therapeutic dose matters: patients in STEP-1 on lower doses showed proportionally lower weight loss.

The Compounding Potency Variable

A 2024 analysis by the FDA found that some compounded semaglutide products tested below labeled potency [7]. If a vial labeled as 5 mg/mL is actually 3.5 mg/mL, the patient is being undertreated. They may interpret the lack of results as a personal failure rather than a product quality issue. This is a real and underreported problem in the compounded GLP-1 space.

Cardiovascular Benefit: The SELECT Trial

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in patients with established cardiovascular disease and overweight or obesity (hazard ratio 0.80; 95% CI 0.72 to 0.90) [11]. This is the evidence base behind the FDA's expanded Wegovy indication for cardiovascular risk reduction in 2024. Compounded semaglutide has not been studied in cardiovascular outcomes trials. Whether equivalent cardiovascular benefit follows from a compounded product with unverified bioequivalence is unknown.

What Patients Report: Synthesizing Curex Reviews

Patient reviews of Curex on third-party platforms like Trustpilot and Reddit's r/GLP1 community show a consistent pattern across the telehealth compounded GLP-1 space.

Positive reports cluster around:

• Lower cost compared to brand medications
• Fast approval turnaround (often 24 to 48 hours)
• Convenience of home delivery

Negative reports cluster around:

• Inconsistent medication potency or formulation changes
• Difficulty reaching prescribers for dose adjustment
• Concern about what happens if the FDA tightens compounding rules further

The FDA's February 2025 removal of semaglutide from the shortage list [2] is the most significant near-term risk for patients currently using compounded GLP-1 services. 503A pharmacies were given a 90-day wind-down period. Patients mid-treatment need a plan: either transition to brand Wegovy or Ozempic (with insurance or manufacturer savings programs) or accept that supply may become legally unavailable.

Is Curex Worth It? A Clinical Perspective

"Worth it" depends on where a patient sits on the access spectrum. For a commercially insured patient who has not tried insurance prior authorization for Wegovy, the answer is probably no. The prior auth process is frustrating but preserves access to an FDA-approved, potency-verified product.

For an uninsured patient with a BMI of 35 and hypertension who cannot afford $1,300 per month, a compounded option at $250 per month with a clinician-reviewed intake is meaningfully better than no treatment. Obesity has a 40-year-plus body of evidence linking it to type 2 diabetes, hypertension, obstructive sleep apnea, and cardiovascular mortality [16]. Deferring treatment while waiting for a perfect access pathway carries its own clinical cost.

The honest answer is that Curex, like most GLP-1 telehealth platforms, exists in a gap created by the US healthcare system's failure to make evidence-based obesity medications accessible at scale. It is not the ideal delivery mechanism for a serious chronic disease. But for some patients, it is the available one.

Any patient using Curex or a similar service should:

1. Request the name and license number of their prescribing clinician and verify it with their state medical board.
2. Ask for the name and FDA registration status of the dispensing pharmacy.
3. Ensure the prescription is for semaglutide base, not a salt form.
4. Establish a monitoring plan that includes at minimum blood pressure checks and a note of any GI side effects, which should be reported to the prescriber.
5. Have a transition plan in case compounded supply is restricted.

The AACE 2023 obesity guidelines recommend a goal of at least 5% body weight reduction to achieve meaningful metabolic benefit, with greater reductions associated with improved glycemic, cardiovascular, and hepatic outcomes [3]. Patients and clinicians should assess response at 12 to 16 weeks and, if less than 5% weight loss has occurred, reevaluate adherence, dose, and product quality before continuing.